DGEN: AI 评分 51/100 — AI 分析 (4月 2026)

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry, offering biological models and drug targets. The company focuses on enhancing drug discovery efficiency and providing target validation data, particularly in immunology and metabolic diseases.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Deltagen Inc. delivers drug discovery tools and services, offering biological models and target validation data to biopharmaceutical companies. Specializing in immunology and metabolic diseases, Deltagen aims to improve drug discovery efficiency. The company operates within the medical instruments and supplies sector, providing crucial resources for pharmaceutical innovation.

DGEN是做什么的？

Deltagen Inc., established in 1999 and headquartered in San Mateo, California, is a key provider of drug discovery tools and services to the biopharmaceutical industry. The company was founded with the mission to accelerate and enhance the drug discovery process. Deltagen offers a comprehensive suite of programs designed to improve the efficiency of drug discovery, including access to a variety of biological models, as well as small-molecule and secreted protein drug targets. These resources enable biopharmaceutical companies to identify and validate potential drug candidates more effectively. Deltagen's core offerings include target validation data, with a particular focus on the areas of immunology and metabolic diseases. By providing high-quality, validated data, Deltagen helps its clients to de-risk their drug discovery efforts and make more informed decisions about which targets to pursue. The company's services are utilized by a range of biopharmaceutical companies, from small startups to large multinational corporations. Deltagen's commitment to innovation and quality has established it as a trusted partner in the drug discovery process.

DGEN的投资论点是什么？

Deltagen Inc. operates in the attractive drug discovery tools and services market, benefiting from the increasing R&D spending in the biopharmaceutical industry. With a gross margin of 99.5%, the company demonstrates a strong ability to generate revenue from its services. However, the company's negative profit margin of -6.0% and negative ROE of -2.7% indicate challenges in achieving profitability. The high beta of 76.36 suggests significant volatility relative to the market. Potential catalysts include successful expansion of its target validation data offerings and strategic partnerships with larger pharmaceutical companies. The company's debt-to-equity ratio of 1.46 indicates a moderate level of financial leverage. Investors should closely monitor Deltagen's ability to improve its profitability and manage its financial risks.

DGEN在哪个行业运营？

Deltagen Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by continuous innovation and increasing demand for advanced drug discovery tools and services. The biopharmaceutical industry's growing R&D expenditure drives the demand for companies like Deltagen. The competitive landscape includes companies offering similar drug discovery tools and services, requiring Deltagen to differentiate itself through innovation and quality of data. Market trends include a focus on personalized medicine and the development of targeted therapies, which further increases the need for efficient target validation and drug discovery processes.

Medical Instruments & Supplies

Healthcare

DGEN有哪些增长机遇？

Expansion of Target Validation Data Offerings: Deltagen can expand its target validation data offerings to cover a broader range of therapeutic areas beyond immunology and metabolic diseases. This expansion would allow the company to tap into new markets and attract a wider range of biopharmaceutical clients. The market for target validation services is estimated to grow as the biopharmaceutical industry increasingly focuses on developing targeted therapies. Timeline: Within the next 2-3 years.
Strategic Partnerships with Pharmaceutical Companies: Forming strategic partnerships with larger pharmaceutical companies can provide Deltagen with access to new markets, funding, and expertise. These partnerships can also help Deltagen to validate its technology and expand its customer base. The biopharmaceutical industry is increasingly relying on partnerships to drive innovation and accelerate drug discovery. Timeline: Ongoing.
Development of AI-Powered Drug Discovery Tools: Investing in the development of AI-powered drug discovery tools can enhance Deltagen's capabilities and provide a competitive advantage. AI can be used to analyze large datasets, identify potential drug targets, and predict the efficacy of drug candidates. The market for AI in drug discovery is growing rapidly, driven by the increasing availability of data and the need for more efficient drug discovery processes. Timeline: Within the next 3-5 years.
Geographic Expansion: Expanding its geographic presence can allow Deltagen to tap into new markets and diversify its revenue streams. The company can focus on expanding into emerging markets with growing biopharmaceutical industries, such as China and India. The global market for drug discovery tools and services is growing, driven by increasing R&D spending in emerging markets. Timeline: Ongoing.
Focus on Personalized Medicine: By focusing on personalized medicine, Deltagen can tailor its drug discovery tools and services to meet the specific needs of individual patients. This approach can lead to the development of more effective and targeted therapies. The market for personalized medicine is growing rapidly, driven by advances in genomics and other technologies. Timeline: Ongoing.

Gross Margin of 99.5% indicates a strong ability to generate revenue from its services.
Profit Margin of -6.0% reflects challenges in achieving profitability.
Return on Equity (ROE) of -2.7% suggests inefficient use of equity to generate profits.
Debt-to-Equity Ratio of 1.46 indicates a moderate level of financial leverage.
Beta of 76.36 indicates high volatility compared to the market.

DGEN提供哪些产品和服务？

Provides drug discovery tools to biopharmaceutical companies.
Offers biological models for drug discovery.
Provides small-molecule and secreted protein drug targets.
Offers target validation data in immunology.
Offers target validation data in metabolic diseases.
Enhances the efficiency of drug discovery processes.

DGEN如何赚钱？

Generates revenue by providing access to biological models.
Generates revenue by providing small-molecule and secreted protein drug targets.
Generates revenue by providing target validation data.
Offers subscription-based access to its drug discovery platform.

Biopharmaceutical companies
Pharmaceutical companies
Drug discovery research institutions

Proprietary biological models
Expertise in target validation
Established relationships with biopharmaceutical companies

什么因素可能推动DGEN股价上涨？

Upcoming: Potential strategic partnerships with larger pharmaceutical companies to expand market reach.
Ongoing: Expansion of target validation data offerings to cover a broader range of therapeutic areas.
Ongoing: Development and integration of AI-powered drug discovery tools to enhance efficiency.

DGEN的主要风险是什么？

Potential: Intense competition from larger, more established drug discovery companies.
Potential: Changes in regulatory requirements impacting drug discovery processes and data validation.
Ongoing: Economic downturn potentially affecting R&D spending in the biopharmaceutical industry.
Potential: Technological advancements rendering current drug discovery tools and services obsolete.

DGEN的核心优势是什么？

Specialized expertise in drug discovery tools and services
Strong focus on immunology and metabolic diseases
High gross margin of 99.5%
Proprietary biological models

DGEN的劣势是什么？

Negative profit margin of -6.0%
Negative ROE of -2.7%
High beta of 76.36
Limited financial resources

DGEN有哪些机遇？

Expansion of target validation data offerings
Strategic partnerships with pharmaceutical companies
Development of AI-powered drug discovery tools
Geographic expansion into emerging markets

DGEN面临哪些威胁？

Competition from larger drug discovery companies
Changes in regulatory requirements
Economic downturn affecting R&D spending
Technological obsolescence

DGEN的竞争对手是谁？

Unknown — Offers similar drug discovery tools and services. — (Unknown)

Key Metrics

MoonshotScore: 51/100

AI Insight

AI analysis pending for DGEN

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Deltagen Inc. do?

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry, focusing on enhancing the efficiency of drug discovery. The company offers a suite of programs, including access to biological models, small-molecule and secreted protein drug targets, and target validation data. Deltagen specializes in providing target validation data in the areas of immunology and metabolic diseases, helping biopharmaceutical companies identify and validate potential drug candidates more effectively. The company's services are utilized by a range of clients, from small startups to large multinational corporations.

What do analysts say about DGEN stock?

As of 2026-03-18, there is no available analyst consensus on DGEN stock. Key valuation metrics such as price-to-earnings ratio and price-to-sales ratio cannot be accurately assessed due to the company's current lack of profitability. Growth considerations revolve around Deltagen's ability to expand its target validation data offerings, form strategic partnerships, and develop AI-powered drug discovery tools. Investors should closely monitor the company's progress in improving its profitability and managing its financial risks.

What are the main risks for DGEN?

Deltagen Inc. faces several risks, including intense competition from larger drug discovery companies with greater resources. Changes in regulatory requirements could impact the company's drug discovery processes and data validation procedures. An economic downturn could reduce R&D spending in the biopharmaceutical industry, affecting demand for Deltagen's services. Technological advancements could render the company's current drug discovery tools and services obsolete. Additionally, the company's negative profit margin and ROE pose financial risks.